Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $6.8750.

A number of brokerages have recently commented on SRTS. Wall Street Zen cut Sensus Healthcare from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. Maxim Group decreased their price objective on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a research note on Thursday, January 22nd. Finally, Alliance Global Partners started coverage on shares of Sensus Healthcare in a report on Friday. They set a “buy” rating and a $7.50 price objective on the stock.

Sensus Healthcare Stock Down 0.7%

Sensus Healthcare stock opened at $4.25 on Monday. The firm has a 50 day moving average price of $4.54 and a 200-day moving average price of $3.90. Sensus Healthcare has a twelve month low of $3.03 and a twelve month high of $5.92. The company has a market capitalization of $69.96 million, a P/E ratio of -9.04 and a beta of 1.22.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.10). Sensus Healthcare had a negative net margin of 28.09% and a negative return on equity of 15.11%. The firm had revenue of $4.94 million during the quarter, compared to analysts’ expectations of $8.35 million. Equities analysts expect that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Pacific Ridge Capital Partners LLC grew its stake in Sensus Healthcare by 21.8% in the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock valued at $2,781,000 after buying an additional 125,245 shares in the last quarter. Divisadero Street Capital Management LP boosted its holdings in shares of Sensus Healthcare by 39.5% in the third quarter. Divisadero Street Capital Management LP now owns 452,897 shares of the company’s stock worth $1,422,000 after acquiring an additional 128,224 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Sensus Healthcare by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 158,240 shares of the company’s stock worth $630,000 after acquiring an additional 5,316 shares during the period. Sachetta LLC grew its position in shares of Sensus Healthcare by 6.8% in the fourth quarter. Sachetta LLC now owns 148,508 shares of the company’s stock valued at $591,000 after purchasing an additional 9,500 shares in the last quarter. Finally, Greenline Wealth Management LLC bought a new stake in shares of Sensus Healthcare during the 4th quarter valued at $513,000. 25.30% of the stock is owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.